Priyanka PullaReporting for this story was supported by a journalism grant from the Thakur Family Foundation, which has not influenced the contents of this report.India’s drug regulator approved two COVID-19 vaccines on 3 January, a decision prime minister Narendra Modi hailed on Twitter as “a decisive turning point to strengthen a spirited fight!” against the pandemic and a testament to the Indian scientific community’s self-reliance.
But some scientists and patient advocates are sharply critical of the move—in particular the decision to greenlight Covaxin, a vaccine developed in India by Bharat Biotech, without awaiting the results of a phase III trial to determine efficacy and safety.At a Sunday press conference, the Drugs Controller.
Read more on sciencemag.org